Results: Program Guide – ASCO Meeting Program GuideIn Phase 1, four patients were enrolled into each of the three cohorts at 10 μg/dose, 50 μg/dose and 100 μg/dose IMU-201 with no DLTs observed. In the 10 μg/dose cohort, one patient achieved CR and one patient SD; in the 50 μg/dose cohort, four patients achieved SD; and in the 100 μg/dose cohort, one patient achieved PR and two patients achieved SD. Within the 100 μg/dose cohort, one patient experienced an immune related pneumonitis after two IMU-201 administrations and discontinued from study treatment.Conclusions:IMU-201 had no observed DLT and demonstrated preliminary signs of efficacy. The study will therefore move into Phase 1b with IMU-201 being assessed in combination with atezolizumab. Clinical trial information: NCT04432207.
Ann: IMUGENE ANNOUNCES PUBLICATION OF ASCO 2022 PD1-VAXX ABSTRACT, page-2
-
- There are more pages in this discussion • 114 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.5¢ |
Change
0.003(5.77%) |
Mkt cap ! $404.2M | |||
| Open | High | Low | Value | Volume |
| 5.2¢ | 5.7¢ | 5.2¢ | $802.5K | 14.79M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 348447 | 5.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.5¢ | 1214875 | 6 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| IMU (ASX) Chart |